Abstract
The effect of the antiepileptics valpromide and sodium valproate on the cytosolic epoxide hydrolase was studied in human fetal liver, kidneys and adrenals and from human adult liver and kidneys. Trans-stilbene oxide was used as substrate. Valpromide (10 mM) lowered the activity of the epoxide hydrolase to one half of the control in all organs studied. Sodium valproate (10 mM) was less powerful as an inhibitor than valpromide; however, it exerted a significant inhibition in all tissues studied.
This is a preview of subscription content, log in via an institution to check access.
References
Gill SS, Hammock BD (1980) Distribution and properties of a mammalian soluble epoxide hydrase. Biochem Pharmacol 29: 389–395
Guenthner TM, Hammock BD, Vogel U, Oesch F (1981) Cytosolic and microsomal epoxide hydrase are immunologically distinguishable from each other in the rat and mouse. J Biol Chem 256: 3163–3165
Hammock BD, Ota K (1983) Differential induction of cytosolic epoxide hydrolase, microsomal epoxide hydrolase and glutathione S-trans-ferase activities. Toxicol Appl Pharmacol 71: 254–256
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with Folin phenol reagent. J Biol Chem 193: 265–275
Mertes I, Fleischmann R, Glatt HR, Oesch F (1985) Interindividual variations in the activities of cytosolic and microsomal epoxide hydrolase in human liver. Carcinogenesis 6: 219–223
Oesch F (1979) Epoxide hydratase. In: Bridges JW, Chasseaud FL (eds) Progress in drug metabolism. Vol 3, John Wiley, Chichester, pp 253–301
Ota K, Hammock BD (1980) Cytosolic and microsomal epoxide hydrolases: differential properties in mammalian liver. Science 207: 1479–1481
Pacifici GM, Colizzi C, Giuliani L, Rane A (1983) Cytosolic epoxide hydrase in fetal and adult human liver. Arch Toxicol 54: 331–341
Pacifici GM, Franchi M, Bencini C, Rane A (1986) Valpromide inhibits human epoxide hydrolase. Br J Clin Pharmacol 22: 269–274
Pacifici GM, Rane A (1987) Valpromide but not sodium hydrogen divalproate inhibits epoxide hydrolase in human liver. Pharmacol Toxicol 60: 237–239
Pacifici GM, Temellini A, Giuliani L, Rane A, Thomas H, Oesch F (1988) Human cytosolic epoxide hydrolase: development and tissue distribution. Arch Toxicol 62: 254–257
Pacifici GM, Tomson T, Bertilsson L, Rane A (1985) Valpromide/carbamazepine and risk of teratogenicity. Lancet i: 397
Pisani F, Fario A, Oteri G, Di Perri R (1981) Dipropylacetic acid levels: Diurnal fluctuations during chronic treatment with dipropylacetamide. Ther. Drug Monitoring 3: 297–301
Pisani F, Fario A, Oteri G, Di Perri R (1982) A study on the metabolism of dipropylacetamide to dipropylacetic acid in rats. J Pharm Pharmacol 34: 45–46
Rettie AE, Rettenmeier AW, Beyer BK, Baillie TA, Juchau MR (1986) Valproate hydroxylation by human fetal tissues and embryotoxicity of metabolites. Clin Pharmacol Ther 40: 172–177
Schladt L, Hartmann R, Timms C, Strolin-Benedetti M, Dostert P, Worner W, Oesch F (1987) Concomitant inducibility of cytosolic epoxide hydrolase in male Sprague-Dawley rats. Biochem Pharmacol 36: 345–351
Schladt L, Worner W, Setiabudi F, Oesch F (1986) Distribution and inducibility of cytosolic epoxide hydrolase in Male Sprague-Dawley rats. Biochem Pharmacol 35: 3309–3316
Sims P, Grover PL (1974) Epoxides in polycyclic aromatic hydrocarbon metabolism and carcinogenesis. Adv Cancer Res 30: 165–274
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pacifici, G.M., Temellini, A., Giuliani, L. et al. Valpromide is a poor inhibitor of the cytosolic epoxide hydrolase. Arch Toxicol 63, 157–159 (1989). https://doi.org/10.1007/BF00316440
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00316440